ESC Heart Failure · 2018 · 19 citations · 20 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyHemodynamic ManagementPharmacodynamicsCardiac BiomarkersCardiac PhysiologyCardiovascular PathophysiologyHeart FailureCardiac Magnetic Resonance BiomarkersVasopressin ReleaseVasopressin SecretionVentricular Ejection Fraction Assessment
AIMS: The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well-known inhibitor of AVP secretion) in HF is unknown. METHODS AND RESULTS: We studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme-linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83-1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6-0.77 pg/mL; P = 0.0002). Heart failure with preserved ejection fraction (but not HFrEF) was a significant predictor of higher AVP after adjustment for potential confounders. Arginine vasopressin levels were independently associated with a greater LA volume and also paradoxically, with lower ANP levels. Key independent correlates of higher AVP were the presence of HFpEF (standardized β = 0.32; 95% CI = 0.09-0.56; P = 0.0073) and the ANP/LA volume ratio (standardized β = -0.23; 95% CI = -0.42 to -0.04; P = 0.0196). Arginine vasopressin levels were independently associated with LV mass (β = 0.26; 95% CI = 0.09-0.43; P = 0.003) and with an increased risk of death or HF admissions during follow-up (hazard ratio = 1.61; 95% CI = 1.13-2.29; P = 0.008). CONCLUSIONS: Arginine vasopressin is increased in HFpEF and is associated with LV hypertrophy and poor outcomes. Higher AVP is associated with the combination of LA enlargement and paradoxically low ANP levels. These findings may indicate that a relative deficiency of ANP (an inhibitor of AVP secretion) in the setting of chronically increased LA pressure may contribute to AVP excess.
20
2013 ACCF/AHA Guideline for the Management of Heart Failure
Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt et al. · Journal of the American College of Cardiology · 2013 · 12.6K citations
Sherif F. Nagueh, Otto A. Smiseth, Christopher P. Appleton et al. · Journal of the American Society of Echocardiography · 2016 · 6.7K citations · Full text
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt et al. · Circulation · 2013 · 3.3K citations
Gary S. Francis, Claude R. Benedict, David E. Johnstone et al. · Circulation · 1990 · 1.4K citations
Medicine, Cardiology, Physiology +10
Julio A. Chirinos, Patrick Segers, Marc De Buyzere et al. · Hypertension · 2010 · 258 citations · Full text
Medicine, Biostatistics, Cardiology +17